2010 Annual Meeting | Challenging Pain Patients

Date Monday 04/12/10

Time 09:00 AM - 05:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Full-Day Course

Director(s) John Markman, MD, FAAN

Topic(s)

Learning Objectives Participants should be able to recognize patients experiencing chronic neuropathic pain and apply an evidence-based approach to their treatment; understand the limitations of the current evidence base as derived from clinical trials; assess the indications for newly introduced and modified analgesic approaches; evaluate the psychosocial factors which commonly modulate pain intensity and activity limitation.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
09:00 AM - 09:50 AM		Demonstrating Neuropathic Pain Treatment Efficacy: Many a Slip ‘Twixt Cup and Lip Robert H. Dworkin, PhD
09:50 AM - 10:05 AM		Break
10:05 AM - 10:55 AM		Somatization and Aberrant Behavior Ronald M. Kanner, MD, FAAN
10:55 AM - 11:10 AM		Questions and Answers
11:10 AM - 12:00 PM		Life After Screws: Diagnosis and Management of Back Pain after Spinal Surgery John Markman, MD, FAAN
12:00 PM - 01:00 PM		Lunch
01:00 PM - 01:50 PM		Options and Indications for Procedural Treatment of Trigeminal Neuralgia Babak S. Jahromi, MD, PhD, FRCSC
01:50 PM - 02:40 PM		Measuring Pain and Figuring Out What Works in Individuals and Groups of Patients with Chronic Neuropathic Pain John T. Farrar, MD
02:40 PM - 02:55 PM		Questions and Answers
02:55 PM - 03:45 PM		How Functional Neuroimgaging Will Transform the Diagnosis and Treatment of Central Neuropathic Pain Conditions Sean Mackey, MD, PhD
03:45 PM - 04:00 PM		Break
04:00 PM - 05:00 PM		Indications for Opioid Therapy in Patients with Painful Polyneuropathy Misha-Miroslav Backonja, MD

Faculty Disclosures
Misha-Miroslav Backonja, MD	Dr. Backonja has nothing to disclose.
John T. Farrar, MD	Dr. Farrar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertex Pharma. Dr. Farrar has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for PharamcoEpidemiology and Drug Safety. The institution of Dr. Farrar has received research support from Food and Drug Administration . The institution of Dr. Farrar has received research support from NIH .
Ronald M. Kanner, MD, FAAN	No disclosure on file
John Markman, MD, FAAN	Dr. Markman has received personal compensation for serving as an employee of Eli LIlly.
Robert H. Dworkin, PhD	Robert H. Dworkin, PhD has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia, Akigai, Allay, AM-Pharma, Analgesic Solutions, Beckley, Biogen, Biosplice, Bsense, Cardialen, Chiesi, Clexio, Collegium, CombiGene, Confo, Contineum, Eccogene, Editas, Eli Lilly, Emmes, Endo, Epizon, Exicure, GlaxoSmithKline, Glenmark, Gloriana, JucaBio, Kriya, Mainstay, Merck, Mind Medicine, NeuroBo, Noema, OliPass, Orion, Oxford Cannabinoid Technologies, Pfizer, Q-State, Regenacy, Rho, Sangamo, Semnur, SIMR Biotech, Sinfonia, SK Biopharmaceuticals, Sparian, SPM Therapeutics, SPRIM Health, Tiefenbacher, Validae, Vertex, Viscera, and WCG.
Sean Mackey, MD, PhD	No disclosure on file
Babak S. Jahromi, MD, PhD, FRCSC	No disclosure on file

��ɫ��

��ɫ��